Company Information

    Kymera Therapeutics was founded on January 2017. The company is based in Cambridge, MA, USA . The number of employees in Kymera Therapeutics is less than 50. Kymera therapeutics is a biotechnology company that specializes in the field of targeted protein degradation.

    Here is how Kymera Therapeutics describes itself: "Advancing targeted protein degradation to deliver next-generation medicines"
      If you are the founder or part of the founding team, please tell the world your story


          Funding & investors

          Kymera Therapeutics has received 4 rounds of venture funding. The total funding amount is around $197M.

            Similar Companies [beta]

              Venture Categories

                Active Venture Investors




                  Venture Competitors

                    News

                        Kymera Therapeutics - Blog

                          • SITC 2021, November 10-14, 2021

                          • Presentation: Targeted STAT3 Degradation Leads to Remodeling of an Immunosuppressive Tumor Microenvironment and Subsequent Sensitization to Immune Checkpoint InhibitionThe post SITC 2021, November 10-14, 2021 appeared first on Kymera Therapeutics.
                          • 4th Annual TPD Summit, October 28, 2021

                          • Presentation: Considerations for E3 Ligase Pairing and Screening of Immune-Inflammation TargetsThe post 4th Annual TPD Summit, October 28, 2021 appeared first on Kymera Therapeutics.
                          • 4th Annual TPD Summit, October 27, 2021

                          • Presentation: Understanding PK/PD for Development of STAT3 Degraders in Oncology IndicationsThe post 4th Annual TPD Summit, October 27, 2021 appeared first on Kymera Therapeutics.
                          • Safety, PK and PD from Single Ascending Does Portion of KT-474 Phase 1 Trial in Healthy Volunteers

                          • Presentation: Safety, PK and PD from Single Ascending Does Portion of KT-474 Phase 1 Trial in Healthy VolunteersThe post Safety, PK and PD from Single Ascending Does Portion of KT-474 Phase 1 Trial in Healthy Volunteers appeared first on Kymera Therapeutics.
                          • 4th Annual TPD Summit, October 26-29, 2021

                          • Presentation: TPD Workshop C: De-risking Clinical Development of a Novel Protein DegraderThe post 4th Annual TPD Summit, October 26-29, 2021 appeared first on Kymera Therapeutics.
                          • European Protein Degradation Congress, September 21st-23rd, 2021

                          • Presentation: Identification of Highly Potent and Selective Interleukin-1 Receptor Associates Kinase 4 (IRAK4) Degrader for the Treatment of Autoimmune DiseaseThe post European Protein Degradation Congress, September 21st-23rd, 2021 appeared first on Kymera Therapeutics.

                          Share:     facebook    twitter    linkedin    reddit    email

                            Ventures Media is one of the largest startup and venture capital communities for startup and venture capital funding information and analysis.

                            Leave a Reply

                            Your email address will not be published. Required fields are marked *